News
The Delaware Supreme Court rejected the legitimacy of expert testimony linking the heartburn drug Zantac to cancer, in a ...
Delaware's Supreme Court sides with drugmakers including GSK (GSK) and Pfizer (PFE), rejecting expert testimony linking ...
In the latest twist in the ocean of Zantac-related litigation playing out across state courts, drugmakers have notched a key ...
Delaware's highest court ruled on Thursday that patients suing drugmakers GSK, Pfizer, Sanofi and Boehringer Ingelheim cannot ...
Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be ...
Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...
Explore more
3d
GlobalData on MSNBoehringer begins Phase II trial of BI 1815368 for diabetic macular oedemaThe study targets adults aged 18 years and above affected by a subtype known as centre-involved diabetic macular oedema.
Long-term treatment with ixekizumab does not increase the incidence of malignant neoplasms in patients with psoriasis, PsA, ...
ArisGlobal, an AI-first technology company at the forefront of life sciences and creator of LifeSphere®, today announced that Boehringer Ingelheim has implemented LifeSphere® NavaX™, unlocking new ...
Boehringer Ingelheim has raised hopes of a more patient-friendly option with the start of phase 2 testing of BI 1815368, ...
The Healthy.io, Geisinger and Boehringer Ingelheim partnership showed a 2.5x increase in test completion rates than standard clinical care.
Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results